Every 10-Q that Oric Pharmaceuticals, Inc. (ORIC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ORIC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORIC filings page.
ORIC Pharmaceuticals is a clinical-stage oncology company reporting continued investment in its two lead programs, rinzimetostat and enozertinib. For the quarter ended June 30, 2026, it recorded a net loss of $41.5 million and for the first half of 2026 a net loss of $77.3 million, driven mainly by research and development spending.
Quarterly R&D expense was $36.3 million, up from $30.5 million a year earlier, reflecting increased external costs for rinzimetostat as the program advances. General and administrative expense was $9.0 million. ORIC held $387.6 million in cash, cash equivalents and investments as of June 30, 2026, after raising about $59.9 million net through at-the-market equity sales in the first half.
The company initiated its first global Phase 3 registrational trial, Himalayas-1, evaluating rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer, under a supply collaboration with Bayer. Enozertinib continues in Phase 1b studies in EGFR-mutated non-small cell lung cancer, with additional data expected in the second half of 2026. ORIC currently expects its existing cash resources to fund its operating plan into the second half of 2028.
ORIC Pharmaceuticals, Inc. reported a net loss of $35.8M for the quarter ended March 31, 2026, compared with $30.0M a year earlier, as it increased investment in its lead oncology programs.
Research and development expenses rose to $31.4M from $24.6M, driven mainly by higher external costs for prostate cancer candidate rinzimetostat and lung cancer candidate enozertinib, while general and administrative expenses were stable at about $8.2M.
ORIC strengthened its balance sheet with $59.9M of net proceeds from at-the-market stock sales, helping lift total cash, cash equivalents and investments to $419.7M. Management believes this liquidity will fund the current operating plan into the second half of 2028 as the company prepares a Phase 3 trial for rinzimetostat and advances multiple Phase 1b studies for enozertinib.
ORIC Pharmaceuticals filed its Q3 2025 10-Q, reporting a net loss of $32.6 million for the quarter and $99.0 million for the nine months ended September 30, 2025. Operating expenses were $36.7 million in Q3, driven by research and development of $28.8 million and general and administrative of $7.9 million.
Liquidity strengthened: cash, cash equivalents and investments were $413.0 million as of September 30, 2025, supported by financing. During Q3 2025, the company raised $108.7 million net via its ATM through the sale of 10,930,032 shares at a weighted average price of $10.10. In May 2025, it completed a private placement for $125.0 million gross, including pre-funded warrants. Management believes current resources fund the plan into the second half of 2028.
ORIC announced a strategic pipeline prioritization on August 12, 2025, focusing on ORIC-944 and enozertinib, with an approximately 20% workforce reduction and a one-time charge of about $1.9 million. As of November 5, 2025, shares outstanding were 97,389,279. The company highlighted ORIC-944 dose optimization progress and expects an enozertinib data update in the fourth quarter of 2025.
ORIC Pharmaceuticals reported continued clinical progress while strengthening its balance sheet. Cash, cash equivalents and investments totaled $327.7 million as of June 30, 2025, and management believes available resources are sufficient to fund operations into the second half of 2028. The company reported a net loss of $66.4 million for the six months ended June 30, 2025 and an accumulated deficit of $629.2 million.
Clinical updates include ORIC-944 combination data showing a 59% PSA50 response rate (47% confirmed) and 24% PSA90 (all confirmed) in mCRPC, and ORIC-114 advancing with provisional RP2D levels of 80 mg and 120 mg and reported intracranial activity. Financing activity included a $125.0 million private placement closed May 29, 2025, ATM proceeds of $8.9 million through June 30, 2025 and subsequent ATM net proceeds of approximately $108.7 million through August 12, 2025. On August 12, 2025, the company announced a strategic pipeline prioritization that will eliminate its discovery research group, reduce workforce by approximately 20% and incur an estimated one-time cost of $1.9 million.